Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: SCAN-MP
Logo

American Heart Association

  119
  0

Final ID:

Discussant: SCAN-MP

  • Alexander, Kevin  ( Stanford University , Palo Alto , California , United States )
    • Author Disclosures:
    Kevin Alexander: DO have relevant financial relationships ; Consultant:Arbor Biotechnologies:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Prothena:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Intellia:Past (completed) ; Consultant:Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
Discussant: ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis

Nativi-nicolau Jose

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Fontana Marianna, Maurer Mathew, Gillmore Julian, Bender Shaun, Aldinc Emre, Eraly Satish, Jay Patrick, Solomon Scott

More abstracts from these authors:
CRISPR Quagmire: Weighing the Risks of Gene Therapies

Mammen Pradeep, Alexander Kevin

Disparities in the Management and Outcomes of Cardiac Amyloidosis in Underrepresented Populations. -how can we bridge the gaps? 10 minutes

Bullock-palmer Renee, Alexander Kevin

You have to be authorized to contact abstract author. Please, Login
Not Available